Thermo Fisher Scientific (TMO) Stock: Price, Trend, Options & Financials
Thermo Fisher Scientific's price regime, relative strength, unusual-options and unusual-volume history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
TMO closed at $629.27 on Aug 21, 2026. The price is +16.2% from its 50-day average and +17.9% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +40.0%, beating SPY by 36.9%. It remains 2.3% below its 52-week high.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
The close is +16.2% from its 50-day average and +17.9% from its 200-day average. Over three months, TMO returned +40.0% versus +3.1% for SPY.
- vs 50-day
- +16.2%
- vs 200-day
- +17.9%
- From 52W high
- -2.3%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
TMO appeared in a UOA top-30 list on 1 of 62 archived scanner sessions: 0 call-side, 1 put-side and 0 on both lists. The latest session did not place it in either top 30. Its larger composite score was -0.04, below the 1.5 “strong” threshold. That is options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-07-24 | — | #17 |
Latest chain snapshot
2026-08-21Strong-signature cutoff: 1.5. Current OTM volume/OI: 0.292 calls, 0.147 puts.
Curated-manager ownership
2 of the 20 managers in the project's curated 13F set reported a long Thermo Fisher Scientific position in their latest filing, worth $14M in aggregate at each filing's reported value. This is a focused manager panel, not the complete institutional holder list.
| Fund / manager | Position value | Portfolio | Shares | Quarter change | Report date |
|---|---|---|---|---|---|
Duquesne Family Office Stanley Druckenmiller · TMO | $10M | 0.18% | 19,200 | — new | 2026-06-30 |
Baron Capital Group Ron Baron · TMO | $5M | 0.01% | 9,219 | -61.0% reduced | 2026-06-30 |
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open TMO Financials →How TMO trades — the working manual
Thermo Fisher Scientific supplies analytical instruments, laboratory products, diagnostics and services used across research and biopharma production. For the stock, recurring consumables and services provide a base, while instrument budgets, biotech funding, pharmaceutical outsourcing and China demand determine the cyclical layer and the return on a large acquisition-built portfolio.
What can move the tape
- 01Biopharma research, production activity and demand for outsourced development and manufacturing services.
- 02Laboratory instrument placements, replacement cycles and recurring consumables pull-through.
- 03Academic, government and biotechnology funding across major regions.
- 04Productivity, acquisition integration, operating margin and debt reduction.
What can fool the read
- 01Customer destocking and delayed capital budgets can depress instruments and consumables together.
- 02Biotechnology funding cycles can reduce activity among smaller research customers.
- 03China policy and local demand can affect both reported growth and factory utilization.
- 04Acquisition-driven scale adds integration risk and can constrain capital allocation through leverage.
Thermo Fisher Scientific triggered 2 issuer-level flags in the committed 2026-04-01–2026-08-21 archive. The latest was TMO on 2026-07-21: 1.8× its 30-day average volume while the stock moved +3.2% that session.
Not published yet. The local archive has 1 reported TMO events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-08-23 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-08-21 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-08-21 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-08-21 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-16 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-08-23 | JSON ↓ |
TMO stock questions
Is TMO stock in an uptrend?+
TMO is classified in the “established uptrend” regime as of 2026-08-21: the close is +16.2% from its 50-day average and +17.9% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in TMO mean?+
Thermo Fisher Scientific's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the TMO 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are TMO's income statement and cash flow?+
The dedicated TMO Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no TMO earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.